Small Cell Carcinoma of the Cervix - Treatment at Distant Relapse

Background

1. Platinum-Etoposide (EP) - First-Line Backbone

• Etoposide + cisplatin (EP) is the most commonly used regimen and is the benchmark, borrowed from SCLC treatment.
• Carboplatin can replace cisplatin for tolerability.
• EP is used both as initial/adjuvant treatment and at relapse if platinum-free interval allows.
• No dedicated clinical trial for SCCC exists; all data extrapolated from SCLC or from small gynecologic oncology series.
• Miyoshi et al., Anticancer Res 2023: In a systematic review of 1997-2021 data, EP was the most commonly used regimen; paclitaxel/carboplatin was second. Other combinations included: cisplatin/vincristine/bleomycin, cisplatin/irinotecan, and cisplatin/ifosfamide/etoposide. EP tended to have better prognosis than alternatives.

• VAC (vincristine + doxorubicin + cyclophosphamide)
• Paclitaxel + carboplatin (PC) - second most used
• Irinotecan + cisplatin - borrowed from SCLC second-line data
• Topotecan - active in relapsed SCLC; used in recurrent SCCC

2. Immune Checkpoint Inhibitors (ICIs)

• Towner et al., Gynecol Oncol Rep 2022: 3 patients with recurrent neuroendocrine cervical carcinoma - all experienced durable responses to ipilimumab + nivolumab. This combination (mirroring the CheckMate 032/451 data in SCLC) is the most promising ICI regimen for recurrent SCCC.

• Masumoto et al., Anticancer Res 2026: A case of HPV18+ SCCC with CD274 (PD-L1) gene amplification treated with nivolumab at supraclavicular distant relapse - achieved complete response sustained >3 years. Key point: genomic testing (PD-L1 gene amplification) predicted exceptional response.

• In non-SCNE cervical cancer, pembrolizumab + platinum/paclitaxel ± bevacizumab is now Category 1 (NCCN) for recurrent/metastatic disease (KEYNOTE-826). This may be extrapolated to SCCC but is not validated specifically.
• In extensive-stage SCLC, atezolizumab and durvalumab added to EP have shown OS benefit - making them logical candidates in SCCC, particularly if PD-L1 positive.
• Chao et al., Biomed J 2023: ICIs hold significant promise in SCNECC, especially combined with chemoradiation or systemic chemotherapy. PD-L1 testing on tumor tissue is recommended.

3. Targeted Therapy and Molecular Testing

• Comprehensive genomic profiling (next-generation sequencing, NGS) is strongly recommended at relapse.
• Reported actionable alterations in SCCC include: FGFR2 alterations (FGFR2-TACC2 fusion), RB1 loss, MYC amplification, PIK3CA mutations, and PTEN loss.
• Schultheis et al., Mol Oncol 2022: Genomic landscape of SCCC partially overlaps with cervical adenocarcinoma (not SCLC), suggesting cervix-specific targeted options may differ from SCLC.
• CDK4/6 inhibitors, PARP inhibitors (if HRD present), and FGFR inhibitors (e.g., erdafitinib for FGFR2) are theoretical targets in molecularly selected patients.
• Tisotumab vedotin (tissue factor-targeting ADC): approved for second/third-line recurrent cervical cancer broadly; no specific SCCC data but may be used given histology-agnostic approval context.

4. Practical Algorithm for Distant Relapse

5. Key Principles

• Multidisciplinary approach is essential: gynecologic oncology, medical oncology, and radiation oncology.
• Molecular/genomic testing at relapse should be standard - this disease is HPV-driven and may harbor PD-L1 amplification or other targetable alterations.
• Clinical trial enrollment is strongly encouraged given the rarity and absence of prospective data.
• Prognosis at distant relapse is very poor regardless of treatment; goals are often disease control and palliation rather than cure.
• Management closely mirrors extensive-stage SCLC protocols, with modification for the HPV-associated, gynecologic context.

Key References

• Berek & Novak's Gynecology - Neuroendocrine Carcinoma section, p. 2235
• Miyoshi et al. Anticancer Res 2023 (PMID 36974776) - systematic review of EP vs other regimens
• Chao et al. Biomed J 2023 (PMID 37467967) - molecular basis and therapeutic advances
• Mandic et al. Eur J Surg Oncol 2025 (PMID 39095302) - current management review
• Towner et al. Gynecol Oncol Rep 2022 (PMID 35846558) - ipilimumab + nivolumab case series
• Masumoto et al. Anticancer Res 2026 (PMID 41760240) - nivolumab in PD-L1-amplified SCCC, >3-year response